Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MZE829

Phase 2Small molecule

MMaze Therapeutics

MZE829 is one of 2 small molecule programs targeting Proteinuric Kidney Disease. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Proteinuric Kidney DiseaseRecruiting

Proteinuric Kidney DiseasePhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Proteinuric Kidney Disease

#DrugCompanyPhaseTrials

MZE829

MMaze Therapeutics

VX-147

Vertex Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Proteinuric Kidney Disease1 trial

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Recruiting·MMaze Therapeutics·Phase 2·NCT06830629·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MZE829. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MZE829 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MZE829. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Maze Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMaze Therapeutics

Related News